Reduced Expression of C/Ebp Alpha Protein in Hepatocellular Carcinoma Is Associated with Advanced Tumor Stage and Shortened Patient Survival
Resource
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY v.135 n.2 pp.241-247
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Journal Volume
v.135
Journal Issue
n.2
Pages
241-247
Date Issued
2009
Date
2009
Author(s)
TSENG, HSI-HUANG
HWANG, YAW-HUEI
Abstract
CCAAT/enhancer binding protein alpha (C/EBP alpha) is a transcription factor and a tumor suppressor. We aimed to assess its protein expression and prognostic value in human hepatocellular carcinoma (HCC). We conducted a retrospective cohort study on 50 HCC patients and performed immunohistochemistry against C/EBP alpha on tumors and adjacent nontumor specimens. Relationships of C/EBP alpha expression with clinical parameters and patient survival were analyzed. C/EBP alpha expression was not influenced by chronic alcohol exposure, viral hepatitis, or cirrhosis, but was reduced in 60% of HCC. Reduction of C/EBP alpha was associated with advanced tumor stage (P = 0.001). Patients with markedly reduced C/ EBP alpha expression had a significantly shorter survival with a hazard ratio of 5.45 ( 95% confidence interval, 1.93-15.40; P = 0.001). C/EBP alpha may be a potential prognostic marker or therapeutic target in HCC regardless of different etiology.
Subjects
CCAAT/enhancer binding protein alpha
Immunohistochemistry
Hepatocellular carcinoma
Survival
SDGs
Type
journal article